2024-11-19
On the afternoon of November 17, the 2024 China Biopharma Front-Runners Top 100 list was officially released at the Biopharma Investment and Financing Forum, part of the 2024 China Pharmaceutical Industry Development Conference and Shanghai International Biopharma Industry Week.
Singular Medical has been listed in the 2024 China Biopharma Front-Runners – Top 100 Medical Device Companies and was honored as an Innovation Pioneer.
Singular Medical is a leading innovator in the independent development and manufacturing of CRM devices in China, committed to creating high-end CRM solutions for Chinese patients. Its product portfolio includes ICDs, ICMs, CSP systems, and external heart failure monitoring devices. Singular Medical has built an elite team of experienced engineers and industry experts dedicated to delivering high-quality, accessible medical products and services to benefit more patients.
The domestically developed ICD—Ambow® by Singular Medical has broken through technological barriers and has completed the full enrollment for its clinical trial. This product is fully protected by intellectual property rights, offering features such as automatic pacing detection, 40J energy charge and discharge, SVT discrimination, streamlined design, and Bluetooth telemetry. Its performance rivals that of leading imported products, and it has entered the National Medical Products Administration's special approval process for innovative products (green channel).
Another product developed by Singular Medical—the implantable cardiac monitor (ICM)—is fully protected by independent intellectual property rights. It can accurately detect a wide range of arrhythmic ECG signals and features a large ECG storage capacity. As the first domestically developed ICM in China, it uses a titanium shell with excellent biocompatibility. The device breaks traditional technical barriers, supports home-based monitoring, and is the first in its class to include Bluetooth telemetry. This allows real-time ECG data transmission to the cloud via smartphones, enabling faster clinical support. The ICM has passed type testing and animal studies, entered the NMPA’s Special Review Pathway for Innovative Devices (Green Channel), and has completed full clinical enrollment and follow-up.
In 2022, Singular Medical was named "Best Medical Technology Company in China 2022" by Medtech Outlook magazine. In 2023, the company was included in the "Forbes Asia 100 Companies to Watch" list, earning international recognition for its professional capabilities. In May 2024, the company’s ICD product was listed on the "VBEF 2024 Annual Innovation Products in Healthcare and Medical Industry" list, with the industry fully acknowledging the company's outstanding contributions and remarkable achievements in the medical field.
Looking ahead, Singular Medical will continue to uphold innovation, quality, and service as its core values, adhering to a "patient-centered" philosophy. The company will consistently enhance its technological and service capabilities, expand its CRM product portfolio to meet clinical needs, and make outstanding contributions to global healthcare.
Company Introduction
Suzhou Singular Medical Co., Ltd. is a high-tech company focused on the development and industrialization of medical devices for Cardiac Rhythm Management (CRM).
The company's headquarters are located in the Medical Device Industrial Park within the High-Tech Zone of Suzhou, with a 2,800 square meter manufacturing facility. Singular Medical also has research and development centers in Beijing, Irvine (USA), and Minnesota (USA). Starting with the most technically challenging product in the CRM field, the Implantable Cardiac Defibrillator (ICD), Singular Medical has built a comprehensive CRM technology platform. The company is growing to become a supplier of a full range of CRM products in China, capable of providing a complete solution for patients with cardiac arrhythmias, ranging from monitoring and diagnosis to treatment and postoperative follow-up.
[Click to view the original text]
